ASTRAZEN · Health Care · 2026-08-21

Astrazeneca Pharma India Ltd

Stage 4 · wk 5In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹7,415.5
-1.22% today
₹18,539 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Visit company website →
P/E (TTM)
107.2
Forward —
Earnings Growth (YoY)
-23.0%
Revenue +21.7%
ROE
+22.8%
Profit margin +8.1%
Dividend Yield
0.36%
P/B 27.1
vs 52W High
-24.5%
₹7,415.5 lo₹9,827.5 hi
24.5% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 5
1w13w26w
Week 5 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-13.1%
200 DMA: ₹8,537.9 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.73x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -2.3% vs MA50 -3.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S2 41w
S2 27w
S2 28w
S4 21w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 2w → S1 1w → S2 41w → S3 9w → S2 27w → S3 9w → S2 28w → S3 8w → S2 10w → S3 3w → S4 21w → S1 5w → S4 5w current
Total tracked: 168 weeks across 13 stage runs.
1M
-5.8%
3M
-13.6%
6M
-16.7%
YTD
-16.5%
1Y
-14.5%
Scan Membership
Breakout Watch
Latest: 2025-10-23
3 appearances in last 60 days. First seen: 2024-05-28.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S4
Wk 5 · Vol —x
2026-08-20S4
Wk 5 · Vol —x
2026-08-19S4
Wk 5 · Vol —x
2026-08-18S4
Wk 5 · Vol —x
2026-08-17S4
Wk 5 · Vol —x
2026-08-14S4
Wk 4 · Vol —x
2026-08-13S4
Wk 4 · Vol —x
2026-08-12S4
Wk 4 · Vol —x
2026-08-11S4
Wk 4 · Vol —x
2026-08-10S4
Wk 4 · Vol —x
2026-08-07S4
Wk 3 · Vol —x
2026-08-06S4
Wk 3 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹8,119.5
200 DMA
₹8,537.9
52W High
₹9,827.5
52W Low
₹7,415.5
5D Low
₹7,415.5
Resistance levels (recent highs)
20d High
₹8,300
60d High
₹8,729
120d High
₹8,962.5
250d High
₹9,827.5
Next resistance
+11.9%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.